Pharmaceutical care of acute liver injury caused by intravenous amiodarone in a patient with pulmonary embolism-induced heart failure
This article reports the pharmacotherapy process of a clinical pharmacist participating in the treatment of a patient with acute liver injury caused by intravenous injection of amiodarone and pulmonary embolism-induced heart failure.The patient had heart failure complicated with pulmonary embolism and systemic congestion and then developed into acute liver injury,which was aggravated and had the risk of cirrhosis.At the same time,the patient developed drug-induced liver injury due to intravenous injection of amiodarone,which interfered with the clinical formulation of treatment plans.The clinician strengthened treatments of anti-heart failure,anticoagulation,reduction of pulmonary artery pressure and others to relieve the pathological factors of cardiogenic liver injury.The clinical pharmacist suggested stopping amiodarone to exclude the factors of drug-induced liver injury,the clinician adopted the suggestion,and finally the patient's condition was stable and the liver function improved.The analysis of this patient's liver injury and assisting the clinical adjustment of medication are important contents of pharmaceutical monitoring.This article can provide a reference for the diagnosis and treatment of similar cases of acute liver injury.
Pulmonary embolismHeart failureLiver injuryAmiodaronePharmaceutical care
NETL
NSTL
万方数据
